廣州領(lǐng)晟醫(yī)療科技有限公司，Link??Health??Group（以下簡稱“領(lǐng)晟醫(yī)藥”）成立于2012年，注冊資本1063.83萬元，國家高新技術(shù)企業(yè)，坐落于廣州市科學(xué)城，是一家致力于創(chuàng)新藥物研發(fā)和國際技術(shù)引進(jìn)的新型醫(yī)藥企業(yè)。
通過不斷努力，目前領(lǐng)晟醫(yī)藥已完成多層項目儲備，覆蓋臨床前到臨床階段多個新藥品種。主要集中在腫瘤，骨科，消化科、炎癥以及疫苗等領(lǐng)域。我們的業(yè)務(wù)包括與跨國醫(yī)藥公司、海外專業(yè)醫(yī)藥公司、全球領(lǐng)先研發(fā)機構(gòu)等合作，通過專利藥物的授權(quán)引進(jìn)新藥項目，自主研發(fā)新劑型，合作國際多中心臨床試驗，通過合資公司，戰(zhàn)略聯(lián)盟等形式進(jìn)行學(xué)術(shù)推廣以及銷售等。?領(lǐng)晟醫(yī)療目前在歐美有超過20家合作企業(yè)，我們?nèi)匀徊粩嘣跉W美開拓新合作與新業(yè)務(wù)。
作為一家發(fā)展快速的新技術(shù)企業(yè)，具有開拓精神的團隊，優(yōu)質(zhì)的人才是我們領(lǐng)晟發(fā)展的動力和基石。?我們歡迎有能力有激情，有致從事創(chuàng)新藥物開發(fā)的您加入。
公司網(wǎng)站：http://www.healthinlink.com/?

Link Health is a company located in China focusing on research of innovative medicinal products. Since 2014, Link Health has grown itself into a leading company in China for developing first-in-class new drugs. In the last three years, the company has built a pipeline covering 9 Class 2 New Drugs including both licensed-in and self-developed drug candidates. In which, half have been in clinical stage aboard and half will enter the IND in China before the end of 2017. Link Health has a very dynamic team in rapid growth to support the registration,future plan of FDA file and clinical development in Asia and USA.
For more information, please refer to our website: www.healthinlink.com